Objectives: To compare the efficacy and tolerability of formoterol (12 or 24µg twice daily) alone with combined ipratropium bromide and fenoterol in the treatment of chronic obstructive pulmonary ...

What is nasal ipratropium used for? Nasal ipratropium is commonly used to relieve symptoms from a runny nose that is caused by the common cold, allergies, or a condition that causes symptoms like ...

Patients taking ipratropium bromide, an anticholinergic used in the treatment of COPD, may be at an increased risk for cardiovascular events (CVE), including heart failure. Patients taking ipratropium ...

We conducted a cohort study to examine the association between anticholinergic use and CVEs in a cohort with newly diagnosed COPD. In our study, we found an increased risk of CVE associated with the ...

Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

Lupin is releasing Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, which are the generic of Boehringer Ingelheim’s Atrovent Nasal Spray, 0.03% and 0.06%. Ipratropium Bromide Nasal ...

Details concerning the Ipratropium Bromide combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, ...

Ipratropium bromide 20mcg, albuterol 100mcg (equivalent to 120mcg albuterol sulfate); per actuation; inhalation spray; CFC-free. Based on studies, ipratropium bromide appears to inhibit vagally ...

Details concerning the Ipratropium bromide medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and ...

Global pharma major Lupin Limited (Lupin) announced the launch of ipratropium bromide nasal solution (nasal spray), 0.03% and 0.06%, in the United States. Ipratropium bromide nasal solution (nasal ...

RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...